English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Osteoarthritis (OA) represents a significant burden to societies, as it affects quality of life, performance and poses a large healthcare cost. We aimed to describe the use of a single intra-articular (IA) injection of an autologous platelet therapy in the management of osteoarthritis (OA) in a naturally occurring canine model.    Methods  Fifteen police working dogs with bilateral hip OA were treated with 3 ml of platelet concentrate per hip joint, produced with the V-PET kit. Response to treatment was measured by the Canine Brief Pain Inventory (CBPI, divided in pain interference score – PIS, and Pain Severity Score - PSS), Liverpool Osteoarthritis in Dogs (LOAD), Canine Orthopedic Index (COI, divided in four dimensions: function, gait, stiffness and quality of life - QOL) and the Hudson Visual Analogue Scale (HVAS). Seven different time points were considered: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5 and T6 (after 1, 2, 3, 4 and 5 months respectively). Results from each evaluation moment were compared with T0 with a Paired Samples T-Test, and a  p  < 0.05 was set.    Results  Significant differences were observed at T1 ( p  < 0.01 for HVAS, PSS, COI, Gait and QOL;  p  = 0.01 for PIS;  p  = 0.02 for Function; and  p  < 0.05 for Stiffness), T2 ( p  < 0.01 for PSS, PIS and Gait;  p  = 0.01 for COI;  p  = 0.02 for HVAS, Function and QOL; and  p  = 0.04 for Stiffness), T3 ( p  < 0.01 for HVAS, PSS, PIS, Function and Gait;  p  = 0.01 for COI; and  p  = 0.02 for QOL), T4 ( p  < 0.01 for PSS;  p  = 0.03 for PIS and Gait), T5 ( p  < 0.01 for COI, Function and Gait;  p  = 0.03 for PSS, PIS and Stiffness), T6 ( p  < 0.01 for PSS, Function and Gait;  p  = 0.04 for PIS;  p  < 0.05 for COI) and T7 ( p  < 0.01 for PSS, Function and Gait;  p  = 0.01 for COI; and  p  < 0.05 for PIS).    Conclusions  Autologous platelet therapy was used without apparent harm in the subjects. A single administration produced significant improvements, which lasted several months, and therefore warrants further study.

bmc musculoskeletal disorders

A report on the use of a single intra-articular administration of autologous platelet therapy in a naturally occurring canine osteoarthritis model - a preliminary study